精神分裂症、抑郁症和双相障碍患者血浆脂质改变特征
该多队列病例对照研究分析了980例精神疾病患者和572名对照的血浆脂质组,发现精神分裂症患者存在77种脂质的一致改变,且与双相障碍和抑郁症的改变高度相似,脂质模型可高精度区分精神分裂症与对照。
要点
- 精神分裂症患者血浆中77种脂质改变在三个队列间一致。
- 基于脂质的预测模型区分精神分裂症与对照的AUC为0.86-0.95。
- 双相障碍和抑郁症的脂质改变与精神分裂症高度相似。
核心结论
- 精神分裂症伴随可重复的血浆脂质组改变,且与双相障碍和抑郁症 largely 共享。
研究设计与样本
- 多队列病例对照诊断分析,纳入2009年7月17日至2018年5月18日期间西欧、中国和俄罗斯的精神科患者及年龄性别匹配的健康对照。
- 使用液相色谱-非靶向质谱评估血浆脂质组。
- 共纳入980例患者和572名对照,患者包括精神分裂症、双相障碍、抑郁症或首发精神病性发作。
主要发现
- 在全部3个样本队列中,精神分裂症患者(n=436)与对照(n=478)之间有77种脂质显著改变。
- 改变在队列间一致:中国与俄罗斯r=0.75,德国-奥地利与中国r=0.78,德国-奥地利与俄罗斯r=0.82,P<10^-38。
- 基于脂质的预测模型区分精神分裂症与对照的AUC为0.86-0.95。
- 双相障碍(n=184)和抑郁症(n=256)的脂质组改变与精神分裂症相似(r=0.89和r=0.92,P<10^-79)。
- 首发精神病性发作患者及未服药精神分裂症患者的改变与药物关联有限,仅特定脂质受限。
关键数值与推荐
- 精神分裂症与对照间77种脂质显著改变,队列间Pearson相关系数r=0.75-0.82,P<10^-38。
- 脂质预测模型区分精神分裂症与对照的AUC=0.86-0.95。
- 双相障碍和抑郁症与精神分裂症脂质改变的相关系数分别为r=0.89和r=0.92,P<10^-79。
临床怎么用
- 血浆脂质特征可能作为严重精神障碍的特质标志物,有望转化为临床可用的检测方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: No clinically applicable diagnostic test exists for severe mental disorders. Lipids harbor potential as disease markers. OBJECTIVE: To define a reproducible profile of lipid alterations in the blood plasma of patients with schizophrenia (SCZ) independent of demographic and environmental variables and to investigate its specificity in association with other psychiatric disorders, ie, major depressive disorder (MDD) and bipolar disorder (BPD). DESIGN, SETTING, AND PARTICIPANTS: This was a multicohort case-control diagnostic analysis involving plasma samples from psychiatric patients and control individuals collected between July 17, 2009, and May 18, 2018. Study participants were recruited as consecutive and volunteer samples at multiple inpatient and outpatient mental health hospitals in Western Europe (Germany and Austria [DE-AT]), China (CN), and Russia (RU). Individuals with DSM-IV or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnoses of SCZ, MDD, BPD, or a first psychotic episode, as well as age- and sex-matched healthy controls without a mental health-related diagnosis were included in the study. Samples and data were analyzed from January 2018 to September 2020. MAIN OUTCOMES AND MEASURES: Plasma lipidome composition was assessed using liquid chromatography coupled with untargeted mass spectrometry. RESULTS: Blood lipid levels were assessed in 980 individuals (mean [SD] age, 36 [13] years; 510 male individuals [52%]) diagnosed with SCZ, BPD, MDD, or those with a first psychotic episode and in 572 controls (mean [SD] age, 34 [13] years; 323 male individuals [56%]). A total of 77 lipids were found to be significantly altered between those with SCZ (n = 436) and controls (n = 478) in all 3 sample cohorts. Alterations were consistent between cohorts (CN and RU: [Pearson correlation] r = 0.75; DE-AT and CN: r = 0.78; DE-AT and RU: r = 0.82; P < 10-38). A lipid-based predictive model separated patients with SCZ from controls with high diagnostic ability (area under the receiver operating characteristic curve = 0.86-0.95). Lipidome alterations in BPD and MDD, assessed in 184 and 256 individuals, respectively, were found to be similar to those of SCZ (BPD: r = 0.89; MDD: r = 0.92; P < 10-79). Assessment of detected alterations in individuals with a first psychotic episode, as well as patients with SCZ not receiving medication, demonstrated only limited association with medication restricted to particular lipids. CONCLUSIONS AND RELEVANCE: In this study, SCZ was accompanied by a reproducible profile of plasma lipidome alterations, not associated with symptom severity, medication, and demographic and environmental variables, and largely shared with BPD and MDD. This lipid alteration signature may represent a trait marker of severe psychiatric disorders, indicating its potential to be transformed into a clinically applicable testing procedure.
引用
- Tkachev A, Stekolshchikova E, Vanyushkina A, et al. Lipid Alteration Signature in the Blood Plasma of Individuals With Schizophrenia, Depression, and Bipolar Disorder. JAMA Psychiatry. 2023. PMID: 36696101. doi:10.1001/jamapsychiatry.2022.4350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。